ION Exchange Q1 FY27 Earnings Call — Analysis (NSE: IONEXCHANG)

Ion Exchange reclassifies segments to showcase products/services growth, while Q1 profit plunges 49% on legacy project pain and Roha startup costs.

17 Aug 2026 · Analysis by Alpha Inflection

Result quality: watch — Margin pressure. Management sentiment: neutral.

The take

Q1FY27 Operating Income ₹701 Cr ( +20% YoY ) . New guidance — FY28 specialty chemicals segment rev… at least 50% . New story: Segment reclassification for transparency .

Results

Q1FY27 revenue ₹701 Cr +20% YoY; EBITDA ₹32 Cr -49% YoY (margin 4.54%); net profit ₹3 Cr; order book ₹2,473 Cr (excl. Hyundai $52M post-quarter). All five segments grew double-digit topline but chemical margins hit by Roha & geopolitics, treatment solutions still loss-making.

Financial highlights

Guidance

Roha utilization target of 25% in first year under pressure but maintained; specialty chemicals revenue expected to grow at least 50% over next couple of years; consumer products break-even targeted in FY27.

What management committed to

• [Roha plant] utilization target of 25% in the first year of operation is maintained; update to be provided by end of Q2. — 25%, FY27
• [Consumer products segment] to break even in FY27. — break even, FY27
• [Pharma resins] capacity to be expanded by 6x within the next 12 months. — 6x, next 12 months
• [Specialty chemicals] revenue expected to increase by at least 50% over the next couple of years from the INR ~900 Cr FY26 base. — at least 50%, FY28
• Total resin capacity across [Roha and Ankleshwar] plants expected to reach approximately 5x the capacity that existed before construction of the Roha plant, after Phase II and debottlenecking. — ~5x
• A significant part of the other [non-UP] legacy projects, especially the large project, will be completed in [FY27]. — significant part completed, FY27

Key themes

Segment reclassification, Roha ramp-up, legacy project overhang

How the narrative shifted

• Segment reclassification for transparency: Management reclassified engineering into three sub-segments to highlight the growing products, chemicals, and services portfolio, shifting perception beyond EPC.
• Roha resin scale-up and margin recovery: Roha plant ramping to 5x capacity will drive specialty chemicals revenue growth of at least 50% over next few years, though near-term margins are weighed down by startup costs.
• Legacy project overhang persists: The UP government-funded project and one other large legacy contract continue to depress treatment solutions profitability; completion is fund-flow dependent and will spill into FY28.
• International expansion gaining structure: New regional leadership and WQA certification position the company to capture a significant share of North American and other export markets, especially for resins.
• Consumer products scaling to breakeven: Zero B consumer business is growing >30% and is targeting breakeven in FY27, expanding into adjacencies like Nepal and eventually Sri Lanka, Bangladesh.
• Geopolitical and input cost headwinds: Geopolitical tensions and elevated crude-derived raw material costs compressed chemical margins; some moderation expected if crude remains soft.
• Advanced solutions future-proofing: Company is building capabilities in ultra-pure water for semicon/green hydrogen, PFAS destruction, brine valorization, and lithium extraction to capture premium emerging segments.

Operational commentary

• Segment reclassification: Engineering broken into Treatment Solutions, Industrial Products, Lifecycle Services to show product & services mix; ~60% of portfolio now products/chemicals/services.
• Roha resin plant Phase I doubled capacity; Phase II with debottlenecking to reach 5x original Ankleshwar capacity; WQA certification obtained for North America; first-year utilization target under pressure.
• Treatment Solutions dragged by legacy projects (UP and one other large), Q1 EBIT loss ₹17 Cr; GCC dispatches resumed; Hyundai $52M contract won post-quarter, profitable profile.
• Industrial Products EBIT margin surged to 11.89% from <6% driven by water treatment & membranes; second membrane plant in Goa for UF/MBR under expansion.
• Lifecycle Services grew 28% with 9.92% margin; scaling O&M, BOO/BOOT models; 20-year O&M concession in Oman contributing.
• Specialty Chemicals revenue up 21%, EBIT down 52% hit by Roha startup costs (6% margin impact) and absence of FX gain; input cost increases being passed with lag.
• Consumer Products revenue up 33% to ₹112 Cr, loss narrowed to ₹34 Lakh; targeting break-even in FY27.
• International expansion: regional leaders appointed for Americas, APAC, MEA; Europe in progress; targeting overseas markets for resins and products.
• Advanced solutions: pursuing ultra-pure water for semiconductors & green hydrogen; PFAS absorption/destruction technology development.
• Order backlog ₹2,473 Cr (excl Hyundai $52M); bid pipeline robust at ₹9,777 Cr.
• Pharma resins capacity expansion 6x in 12 months at Ankleshwar; FDA-approved facility.

Analyst Q&A

• Q. What would be the ballpark margin profile for specialty chemicals and revenue contribution in 2-3 years?

  It is premature to talk about percentages; specifics will become evident as quarters unfold.

• Q. Could you quantify the revenue contribution from pharma resins?

  We don't provide that breakup; when the segment becomes big enough, we will report separately.

• Q. What is the revenue contribution from the WQA certification and expected growth trajectory?

  We cannot quantify, but a significant part of Roha capacity is expected to cater to North America.

• Q. Is the worst of the treatment solutions P&L pain behind us, and what is the glide path?

  Significant part of project is behind us but sizable portion remains; newer profitable projects will offset over time.

View source

Research and educational content only. Not investment advice.